The obesity market has garnered much interest lately, ever since Novo Nordisk (NVO) received FDA approval for its obesity drug Wegovy in 2021. It was only after a couple of years that the market gained a second entrant – Eli Lilly’s (LLY) Zepbound, which received FDA approval last year in November. Lilly and Novo have been registering top- and bottom-line growth, owing to the vastness of the total market size for obesity. The companies even achieved a market cap north of $500 billion. However, these firms h ...